AbbVie’s upadacitinib meets primary, secondary endpoints in SLEek trial
The phase 2 study was evaluating upadacitinib 30mg alone and in combination (ABBV-599 high dose) in systemic lupus…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Jun 23
The phase 2 study was evaluating upadacitinib 30mg alone and in combination (ABBV-599 high dose) in systemic lupus…
01 Jun 23
The scientists found that the disorder has an overactive version of the STAT4 protein, which controls inflammation and…
31 May 23
In the late-stage trial, the prophylactic treatment with marstacimab showed a statistically significant and clinically relevant reduction in…
31 May 23
Health Canada approved BRUKINSA based on positive efficacy results and a favourable safety profile from two global late-stage…
31 May 23
DMD is the most common form of muscular dystrophy and is a genetic disorder characterised by progressive muscle…
31 May 23
This strategic acquisition allows Anatomy IT to expand its presence in the ambulatory healthcare sector and bring its…
31 May 23
Application based on results from the registrational TRIDENT-1 trial, in which repotrectinib demonstrated high response rates and durable…
31 May 23
FDA is proposing to require a new type of Medication Guide called Patient Medication Information for prescription drugs…
31 May 23
MOSAIC Study is First to use MRI to Assess Inflammation in Peripheral Joints and Entheses in Psoriatic Arthritis…
30 May 23
The approval follows the clearance from China’s National Medical Products Administration in April 2023 for the clinical trial…